GlaxoSmithKline (NYSE:GSK) Downgraded by ValuEngine

ValuEngine downgraded shares of GlaxoSmithKline (NYSE:GSK) from a hold rating to a sell rating in a research note published on Tuesday morning, ValuEngine reports.

GSK has been the subject of several other reports. Cowen reaffirmed a hold rating and issued a $45.00 target price on shares of GlaxoSmithKline in a research note on Monday, June 10th. Societe Generale raised shares of GlaxoSmithKline from a sell rating to a buy rating in a research note on Tuesday, September 3rd. Morgan Stanley reaffirmed an underweight rating on shares of GlaxoSmithKline in a research note on Monday, June 17th. Jefferies Financial Group reaffirmed a buy rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. Finally, JPMorgan Chase & Co. reaffirmed a neutral rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have given a buy rating to the stock. The company has an average rating of Hold and an average price target of $41.79.

Shares of GSK traded down $0.10 during mid-day trading on Tuesday, reaching $40.93. 59,108 shares of the company’s stock were exchanged, compared to its average volume of 2,031,593. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86. The company has a 50-day simple moving average of $41.15 and a two-hundred day simple moving average of $40.58. GlaxoSmithKline has a 52-week low of $36.41 and a 52-week high of $42.49. The company has a market cap of $102.21 billion, a price-to-earnings ratio of 12.94, a PEG ratio of 1.96 and a beta of 0.70.



GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. The business had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. As a group, equities research analysts predict that GlaxoSmithKline will post 2.96 EPS for the current fiscal year.

In related news, Director Plc Glaxosmithkline purchased 333,333 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were bought at an average price of $15.00 per share, for a total transaction of $4,999,995.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.00% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rehmann Capital Advisory Group boosted its holdings in shares of GlaxoSmithKline by 9.9% in the 2nd quarter. Rehmann Capital Advisory Group now owns 4,468 shares of the pharmaceutical company’s stock valued at $179,000 after purchasing an additional 402 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in shares of GlaxoSmithKline in the 2nd quarter valued at $569,000. Kanawha Capital Management LLC boosted its holdings in shares of GlaxoSmithKline by 9.7% in the 2nd quarter. Kanawha Capital Management LLC now owns 53,308 shares of the pharmaceutical company’s stock valued at $2,133,000 after purchasing an additional 4,696 shares during the last quarter. Vestmark Advisory Solutions Inc. boosted its holdings in shares of GlaxoSmithKline by 5.4% in the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 34,131 shares of the pharmaceutical company’s stock valued at $1,366,000 after purchasing an additional 1,759 shares during the last quarter. Finally, Kayne Anderson Rudnick Investment Management LLC boosted its holdings in shares of GlaxoSmithKline by 8.0% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 334,764 shares of the pharmaceutical company’s stock valued at $13,398,000 after purchasing an additional 24,885 shares during the last quarter. Institutional investors own 11.16% of the company’s stock.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: What are the benefits of a portfolio tracker?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.